scholarly journals Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study

2020 ◽  
Vol 9 (2) ◽  
pp. 531-543
Author(s):  
Hida Nierenburg ◽  
Julio R. Vieira ◽  
Nirit Lev ◽  
Tamar Lin ◽  
Dagan Harris ◽  
...  
Keyword(s):  
Pilot Study ◽  
Chronic Migraine ◽  
Acute Treatment ◽  
Open Label ◽  
Electrical Neuromodulation

scholarly journals Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study

PAIN Reports ◽  
2021 ◽  
Vol 6 (4) ◽  
pp. e966
Author(s):  
Brian Grosberg ◽  
Liron Rabany ◽  
Tamar Lin ◽  
Dagan Harris ◽  
Maya Vizel ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Acute Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy ◽  
Electrical Neuromodulation

scholarly journals Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study

2015 ◽  
Vol 16 (1) ◽  
Author(s):  
Piero Barbanti ◽  
Licia Grazzi ◽  
Gabriella Egeo ◽  
Anna Maria Padovan ◽  
Eric Liebler ◽  
...  
Keyword(s):  
Vagus Nerve ◽  
Chronic Migraine ◽  
Nerve Stimulation ◽  
High Frequency ◽  
Vagus Nerve Stimulation ◽  
Acute Treatment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Non Invasive

Transcutaneous supraorbital neurostimulation for acute treatment of chronic migraine: open-label preliminary data

2018 ◽  
Vol 39 (S1) ◽  
pp. 163-164 ◽  
Author(s):  
Paola Di Fiore ◽  
Alberto Galli ◽  
Giacomo D’Arrigo ◽  
Gennaro Bussone ◽  
Henri Didier ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Preliminary Data ◽  
Acute Treatment ◽  
Open Label

scholarly journals Remote Electrical Neuromodulation for the Acute Treatment of Episodic and Chronic Migraine

Neurology ◽  
2021 ◽  
Vol 17 (1) ◽  
pp. 6
Author(s):  
Jennifer W McVige ◽  
Alit Stark-Inbar ◽  
◽  
Keyword(s):  
Chronic Migraine ◽  
Acute Treatment ◽  
Electrical Neuromodulation

scholarly journals Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine

Cephalalgia ◽  
2016 ◽  
Vol 37 (4) ◽  
pp. 356-364 ◽  
Author(s):  
Daniel Fossum Bratbak ◽  
Ståle Nordgård ◽  
Lars Jacob Stovner ◽  
Mattias Linde ◽  
David W Dodick ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Chronic Migraine ◽  
Severe Headache ◽  
Sphenopalatine Ganglion ◽  
Open Label ◽  
Intention To Treat ◽  
Efficacy Outcome ◽  
The Face

Objective The main objective of this pilot study was to investigate the safety of administering onabotulinumtoxinA towards the sphenopalatine ganglion in 10 patients with intractable chronic migraine with an open, uncontrolled design. We also collected efficacy data to provide an indication as to whether future placebo-controlled studies should be performed. Method In a prospective, open-label, uncontrolled study after one-month baseline, we performed bilateral injections of 25 IU onabotulinumtoxinA (total dose 50 IU) toward the sphenopalatine ganglion in a single outpatient session in 10 patients with intractable migraine with a follow-up of 12 weeks. The primary outcome was adverse events and the main efficacy outcome was frequency of moderate and severe headache days in month 2 post-treatment compared to baseline. Results All 10 patients experienced a total of 25 adverse events. The majority of these were different types of local discomfort in the face and jaw, and none were classified as serious. In an intention-to-treat analysis of the main efficacy outcome, a statistically significant reduction of moderate and severe headache days in baseline versus month 2 was observed (16.3 ± 6.2 days baseline versus 7.6 ± 7.6 days month 2, p = 0.009). Eight out of 10 patients experienced an at least 50% reduction of moderate and severe headache days compared to baseline. Conclusion The result warrants randomised, placebo-controlled studies to establish both safety and efficacy of this potential novel treatment of chronic migraine.

Sign in / Sign up

Export Citation Format

Share Document